Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity
摘要:
Antimalarial drug resistance is a serious obstacle in the persistent quest to eradicate malaria. There is a need for potent chemical agents that are able to act on drug-resistant Plasmodium falciparum populations at reasonable concentrations without any related toxicity to the host. By rational drug design, we envisaged to address this issue by generating a novel hybrid drug possessing two pharmacophores that can act on two unique and independent targets within the cell. We synthesized a new class of ciprofloxacinbased hybrid molecules, which have been integrated with acridine, quinolone, sulphonamide, and cinnamoyl pharmacophores (1-4). We realized a potent chloroquinolone-ciprofloxacin-based antimalarial hybrid (2, CQ-CFX) whose mechanism of action is unlike that of its parent molecules indicating a unique biological target. CQ-CFX is not only potent against CQ-resistant and susceptible strains of Plasmodium falciparum at low nanomolar concentrations (IC50 values are 63.17 +/- 1.2 nM and 25.52 +/- 4.45 nM, respectively) but is also not toxic to mammalian and bacterial systems up to 20 mu M and 1 mu M, respectively.
The C=C Bond Decomposition Initiated by Enamine‐Azide Cycloaddition for Catalyst‐ and Additive‐Free Synthesis of
<i>N</i>
‐Sulfonyl Amidines
作者:Xixi Zheng、Jie‐Ping Wan
DOI:10.1002/adsc.201901054
日期:2019.12.17
The chemo‐selective synthesis of N‐sulfonyl amidines is realized via the decomposition of the enamine C=C bond of enaminoesters through an in situ generated triazoline intermediate. Control experiments prove that the electron withdrawing ester group in the enamine component is crucial in inducing the chemo‐selective formation of amidines. The method is featured with high efficiency and sustainability
[EN] IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17<br/>[FR] IMIDAZOPYRIDAZINES EN TANT QUE MODULATEURS DE L'IL-17
申请人:JANSSEN BIOTECH INC
公开号:WO2021222404A1
公开(公告)日:2021-11-04
The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
The derivatization of the fluoroquinolone ciprofloxacin greatly increases its antimalarialactivity by combining bioorganometallic chemistry and the prodrug approach. Two new achiral compounds 2 and 4 were found to be 10- to 100-fold more active than ciprofloxacin against Plasmodium falciparum chloroquine-susceptible and chloroquine-resistant strains. These achiral derivatives killed parasites more
[EN] IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17<br/>[FR] IMIDAZOPYRIMIDINES EN TANT QUE MODULATEURS DE L'IL-17
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2021220183A1
公开(公告)日:2021-11-04
The present application discloses compounds of Formula I or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
6-amino-3-azabicyclo[3.1.0]hexyl side chain of trovafloxacin. The four compounds are also inhibitory for blood stages of Plasmodium falciparum though at high concentration. These results confirm the potential of quinolones as anti-T. gondii and antimalarial drugs but also show that the QSAR models for T. gondii cannot be reliably extended for screening antimalarial activity.